A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, Van der Heijden MS.
Powles T, et al. Among authors: gupta s.
Future Oncol. 2025 Jan 31:1-16. doi: 10.1080/14796694.2024.2415192. Online ahead of print.
Future Oncol. 2025.
PMID: 39889805